Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609808 | 0.85 | SMN1; SMN2 (0.82) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL418939 | 0.82 | CYP17A1 (0.54) | SMN1; SMN2MAPTALDH1A1KDM4ERAB9A | |
| SCHEMBL6004359 | 0.82 | RAB9A (0.58) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL23751560 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL7998395 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTALDH1A1HPGDLMNA | |
| SCHEMBL14861049 | 0.80 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL14509718 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTALDH1A1HPGDLMNA | |
| SCHEMBL201938 | 0.79 | ALDH1A1 (0.64) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL7251623 | 0.79 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPTALDH1A1HPGDLMNA | |
| SCHEMBL2282492 | 0.78 | HPGD (0.65) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20170217984-A1 | Ligands for Alpha-7 Nicotinic Acetylcholine Receptors and Methods of Treating Neurological and Inflammatory Conditions | NORTHEASTERN UNIVERSITY | 2017-08-03 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-1417173-B1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1417173-B1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7045631-B2 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20040176417-A1 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1417173-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | Bayer HealthCare AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003008384-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| EP-0675133-B1 | 13-Substituted milbemycin derivatives, their preparation and use | SANKYO CO (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5614470-A | AGRICULTURAL ANTHELMINTIC, ACARICIDE, INSECTICIDE | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0675133-A1 | 13-Substituted milbemycin derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217984-A1 | Ligands for Alpha-7 Nicotinic Acetylcholine Receptors and Methods of Treating Neurological and Inflammatory Conditions | CHRNA7, CHRNA10, CHRNA5 | SMN1; SMN2 874/4885MAPT 435/4885ALDH1A1 2770/4885 |
| US-20040176417-A1 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | ADORA1, ADORA3, ADORA2A | SMN1; SMN2 4487/4885MAPT 3697/4885ALDH1A1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.